Travere Therapeutics Inc. (TVTX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Travere Therapeutics: Still Undervalued Post FSGS Approval
Travere Therapeutics is rated a BUY following Filspari's landmark FDA approval for FSGS, making it the only approved therapy for this indication. TVTX remains undervalued, with projected peak sales of $2.2–3B across FSGS and IgAN, and a forward PE of 8.84 versus a sector median of ~18. Filspari's commercial launch benefits from cross-selling synergies with IgAN, leveraging existing infrastructure to accelerate FSGS market penetration and reduce costs.
Travere Therapeutics: Re-Rating Potential As Filspari Wins Full Approval
Travere Therapeutics secured full FDA approval for Filspari in FSGS, expanding its rare kidney disease franchise and driving a 37% stock surge. The FSGS approval increases TVTX's U.S. addressable market by 30,000 patients, supporting a multi-year revenue and earnings inflection not yet fully reflected in estimates. Filspari's unique, non-immunosuppressive mechanism and first-mover status in FSGS position TVTX for premium pricing and significant volume-driven revenue growth.
TVTX Stock Soars on FDA Nod for Filspari in Second Kidney Indication
Travere Therapeutics stock jumps 37% after the FDA expands Filspari's use to a second rare kidney disease, boosting its market reach and treatment potential.
Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock?
Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS Transcript
Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS Transcript
US FDA expands approval for Travere Therapeutics' drug for rare kidney disease
The U.S. Food and Drug Administration has approved the expanded use of Travere Therapeutics' drug to treat a rare kidney disorder, the company said on Monday.
Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms
Travere Therapeutics is positioned for upside as FILSPARI sales accelerate and the critical FSGS PDUFA decision approaches in April. FY25 revenue grew 81% to $410.5M, driven by FILSPARI's 144% YoY growth and record patient starts, signaling robust commercial momentum. Profitability metrics improved, with 4Q25 GAAP net income positive and non-GAAP net income at $81.1M, reflecting operating leverage and cost discipline.
Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript
Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript
Travere (TVTX) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates
Travere Therapeutics (TVTX) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.73 per share a year ago.
Travere Therapeutics (TVTX) Earnings Expected to Grow: Should You Buy?
Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Travere Therapeutics: Filspari's FSGS Approval Chance Is Higher Than You Think
Travere Therapeutics (TVTX) is focused on rare kidney diseases, with FILSPARI driving significant revenue growth in IgA Nephropathy (IgAN). Competition in IgAN from larger players like Novartis and Vertex is intensifying, making FILSPARI's FSGS approval pivotal for the company's future growth. FILSPARI's FSGS indication represents a $2 billion U.S. peak sales opportunity, with no current FDA-approved therapies for this disease.
